文献速递浆细胞疾病造血干细胞移植与细胞治疗

硼替佐米为基础方案序贯自体造血干细胞移植治疗伴1q21扩增/获得的初治多发性骨髓瘤患者的预后因素

[Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

回顾性分析35例伴1q21扩增/获得的初治多发性骨髓瘤患者,接受硼替佐米为基础化疗序贯自体造血干细胞移植及维持治疗,ASCT后完全缓解率57.0%,中位随访24个月,合并其他高危细胞遗传学异常者无进展生存和总生存显著缩短。

要点

  • 35例中单纯1q21扩增仅3例(8.6%),其余32例合并其他细胞遗传学异常。
  • ASCT后完全缓解率57.0%,非常好的部分缓解率37.1%,部分缓解率5.7%。
  • 合并其他高危细胞遗传学异常者无进展生存和总生存显著缩短(P=0.020和P=0.006)。

核心结论

  • 1q21扩增很少单独发生,常伴发其他细胞遗传学异常。
  • 硼替佐米为基础化疗序贯ASCT治疗初治多发性骨髓瘤疗效良好,合并其他高危细胞遗传学异常是影响该亚组患者无进展生存和总生存的不良预后因素。

研究设计与样本

  • 回顾性分析2008年1月至2015年8月接受硼替佐米为基础化疗序贯自体造血干细胞移植及移植后维持和(或)巩固治疗的35例伴1q21扩增/获得的初治多发性骨髓瘤患者资料。

主要发现

  • 35例患者中位发病年龄49(33~63)岁,男22例、女13例。
  • 单纯检出1q21扩增者3例(8.6%),其余32例合并其他细胞遗传学异常,包括13q14缺失、t(11;14)、t(4;14)、t(14;16)、17p缺失和复杂核型。
  • ASCT后完全缓解20例(57.0%),非常好的部分缓解13例(37.1%),部分缓解2例(5.7%)。
  • 中位随访24(8~85)个月,预期3年无进展生存率和总生存率分别为(66.5±9.7)%和(69.6±9.9)%。
  • 高危组(13例)中位无进展生存和总生存分别为26个月和28个月,非高危组(22例)分别为54个月和未达到;高危组较非高危组3年预期无进展生存率降低[(28.0±15.9)%对(71.5±12.7)%,χ(2)=5.404,P=0.020],3年预期总生存率降低[(36.5±16.4)%对(92.3±7.4)%,χ(2)=7.596,P=0.006]。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the prognostic factors in newly diagnosed multiple myeloma (NDMM) patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation (ASCT) . Methods: We retrospectively assayed 35 NDMM patients with 1q21 amplification/gain who received bortezomib-based chemotherapy followed by ASCT and maintenance therapy between January 2008 and August 2015. Results: ①The median age of 35 patients were 49(33-63)years old. Ratio of male to female was 22∶13. Monosomy1q21 amplification/gain was only seen in 3(8.6%) patients, the other 32 patients were with additional cytogenetic abnormalities including 13q14 deletion, t(11,14), t(4,14), t(14,16), 17p deletion and complex karyotype aberrations. ②The complete remission (CR) rate was 57.0% (20/35), the very good partial remission(VGPR) rate was 37.1%(13/35) and the partial remission (PR) rate was 5.7%(2/35) after ASCT. At a median follow-up of 24 (8-85) months, 3-year estimated progression free survival (PFS) and overall survival (OS) rate were (66.5±9.7)% and (69.6±9.9)%, respectively. ③As 13 patients with high-risk cytogenetic abnormalities, the median PFS and OS time was 26 and 28 months. The 3-year estimated PFS and OS was (28.0±15.9)% and (36.5±16.4)%, respectively. Another 22 patients without other high-risk cytogenetic abnormalities, the median PFS and OS time was 54 months and not reached. The 3-year estimated PFS and OS was (71.5±12.7)% and (92.3±7.4)% in this group, respectively. The presence of additional other high-risk cytogenetic abnormalities resulted in significantly shortened PFS (χ(2)=5.404, P=0.020) and OS (χ(2)=7.596, P=0.006) compared with no high-risk cytogenetic patients. Conclusion: NDMM patients with isolated1q21 amplification/gain were rarely and usually had additional other cytogenetic abnormalities. The outcomes in this group treated with bortezomib-based chemotherapy followed by ASCT and maintenance therapy were satisfied, additional other high-risk cytogenetic abnormalities made PFS and OS further shortened. 目的: 探讨硼替佐米为基础的化疗序贯自体造血干细胞移植(ASCT)治疗伴有1q21扩增的初治多发性骨髓瘤(MM)患者的疗效和预后影响因素。 方法: 回顾性分析2008年1月至2015年8月以硼替佐米为基础的化疗序贯ASCT以及移植后维持和(或)巩固治疗伴有1q21扩增的35例初治MM患者资料。 结果: ①35例患者中,男22例,女13例,中位发病年龄49(33~63)岁。单纯检出1q21扩增者仅为3例(8.6%),其余32例均合并其他细胞遗传学异常,包括13q14缺失、t(11;14)、t(4;14)、t(14;16)、17p缺失和复杂核型。②ASCT后获得完全缓解者20例(57.0%),获得非常好的部分缓解者13例(37.1%),获得部分缓解者2例(5.7%)。中位随访24(8~85)个月,预期3年无进展生存(PFS)率和总生存(OS)率分别为(66.5±9.7)%和(69.6±9.9)%。③按合并其他高危或非高危细胞遗传学异常对患者进行分组,高危组(13例)中位PFS和OS时间分别为26个月和28个月,非高危组(22例)中位PFS和OS时间分别为54个月和未达到,高危组与低危组3年预期PFS率[(28.0±15.9)%对(71.5±12.7)%,χ(2)=5.404,P=0.020]和OS率[(36.5±16.4)%对(92.3±7.4)%,χ(2)=7.596,P=0.006]差异均有统计学意义。 结论: 1q21扩增很少单独发生,常伴发其他细胞遗传学异常。硼替佐米为基础的化疗序贯ASCT治疗初治MM患者疗效良好,合并其他高危细胞遗传学异常是影响该亚组患者PFS和OS的不良预后因素。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Huang WY, Zou DH, Liu W, et al. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30032568. doi:10.3760/cma.j.issn.0253-2727.2018.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。